Answers are grounded in this paper and cite their sources.
Lyophilized human amniotic membranes (HAM) represent a promising therapeutic resource in regenerative medicine and wound healing owing to their structural integrity, anti-inflammatory and antimicrobial properties, and capacity to serve as a biocompatible barrier. This scoping review aimed to map and synthesize evidence from 2010 to 2025 on the clinical use of lyophilized HAM for managing skin lesions. Following Joanna Briggs Institute (JBI) guidelines, Arksey and O’Malley’s framework, and PRISMA-ScR reporting standards, a systematic search was performed in PubMed, Scopus, and LILACS for studies in English and Spanish, including clinical trials, observational studies, and case series explicitly addressing lyophilized HAM. Thirteen studies met the inclusion criteria, and seven were synthesized, showing considerable methodological heterogeneity. Applications included chronic diabetic and non-diabetic ulcers, burns, and toxic epidermal necrolysis. Across studies, lyophilized HAM promoted accelerated re-epithelialization, pain reduction, infection control, and improved cosmetic outcomes through biological mechanisms involving growth factors, anti-inflammatory cytokines, and extracellular matrix proteins. Despite favorable results, most studies were small and short-term, limiting generalizability. Overall, lyophilized HAM appears to be a safe, cost-effective, and versatile option for wound care, though standardized lyophilization protocols and robust multicenter research are needed to consolidate its clinical integration.
No takes yet. Share an insight, caveat, or question.
Bojanini et al. (2026) studied this question.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: